Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flu inhaled powder vaccine
- Development stage
- Preclinical
- Lead developer
- TechnoVax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
The Flu Inhaled Powder Vaccine is a preclinical-stage virus-like particle (VLP) vaccine being developed by TechnoVax in collaboration with MannKind Corporation. Designed for pandemic influenza preparedness, the vaccine utilizes TechnoVax's VLP technology to create non-infectious particles that mimic the structure of the influenza virus, thereby eliciting a robust immune response against viral antigens such as hemagglutinin. The vaccine is uniquely formulated as a dry powder for intrapulmonary delivery using MannKind's proprietary inhalation technology, which allows for needle-free self-administration. This delivery method is intended to facilitate rapid mass immunization and provide both systemic and mucosal immunity during pandemic outbreaks.
- Other names
- Flu Inhaled Powder VaccineTechnoVax Inhaled Flu VaccineVLP influenza vaccine (inhaled powder)
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on flu inhaled powder vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flu inhaled powder vaccine.